Blocking Dietary Cholesterol
This article was originally published in Start Up
One way to block dietary cholesterol is by inhibiting the microsomal triglyceride transfer protein (MTP). MTP is one mechanism used by the liver and by cells in the gut wall (called enterocytes) to process triglycerides and cholesterol for delivery into the systemic circulation. However, past attempts to inhibit MTP (including at Pfizer, BMS, and Bayer) have faltered because of liver toxicity-fatty liver resulting from overaccumulation of LDL. Scientists at Surface Logix think their approach may fare better because it only blocks MTP in the intestine. (Sidebar to "After Statins, What Next?")
You may also be interested in...
As the global shut-down caused by the coronavirus pandemic continues, sponsors are rushing to adapt clinical trials that can move to partial or completely remote monitoring, allowing patients to remain in their homes but continue to participate in studies. And the outbreak may have another silver lining for the biopharma industry, a chance to rebuild its reputation.
Oncology and rare diseases dominate the industry pipeline, fuelled by science, regulatory tailwinds and high prices. But as the world grapples with coronavirus, and with heart disease still the top killer, can our systems fund treatments for more prevalent conditions?
It has been a bumpy ride for some of the (still modest) number of European biotechs listed on Nasdaq, for various reasons. Yet most expect the direct-to-Nasdaq trend to continue. Europe’s public markets simply cannot compete.